Bluebird bio — Investor Day (December 2015)
73 slides from Bluebird bio's investor day presentation, Dec 7, 2015
Slide 1: Transforming the Lives of Patients with Severe Genetic and Rare Diseases
Transforming the Lives of Patients with Severe Genetic and Rare Diseases Making Hope a Reality Exhibit 99.4
Slide 2: Forward Looking Statement
Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue
Slide 3: Tonight
Tonigt Time Slot (EST) Topic Speaker 8:00 — 8:30 p.m. | Cocktail Reception . | Welcome, Agenda sim DeTore, chief financial officer Opening Remarks Nick Leschly, chief bluebird 35 — 9:05 p.m. WD Beta-thalassemia Major David Davidson, M.D., chief medical officer Sickle Cell Disease David Davidson, M.D
Slide 4: bluebird bio: Why We Do What We Do
bluebird bio: Why We Do What We Do Our Vision – Make Hope a Reality Seeking to transform the lives of patients with severe genetic and rare diseases through the development of innovative gene therapy products. Ethan Cameron Aidan
Slide 5: Figo Ibbrmmatory dernyknaton on in cxobeat
Figo 1 Ibbrmmatory dernyknaton on in cxobeat AD oe 72 mage, rhe pest gosh. a FS 2] Multiple Myeloma Plasma Cells \ bluebird
Slide 6: TRUE BLUE
TRUE BLUE Gaining Mc B4-14-011 100000 evento Rea : et Dosing abteh ae # leocs ove coseoees 29 36 43 50 57 G4 71 78 85 Days {9 product infusio Bing 43 get Hoa" 40%), (9.96. HOS (47%) at Simons Months post-drug product infusion » bluebirdbio’
Slide 7: What is Our Mindset?
What is Our Mindset? Patient centricity across all disciplines Passionate Urgent Humble Patient-Centric Decision Making GT geeks rule – dig deep Data AND product driven Curiousity – no failure in being wrong A’s don’t settle Two ears, one mouth No alligator hands – speak up, step up Leaders galvaniz
Slide 8: The Innovators Dilemma
The Innovators Dilemma DOWNSIDE RISK & FEAR UPSIDE OPTIMISM & HUNGER “DOWNSIDE RISK OF SUCCESS IS CHOICE” Dissatisfied Optimists (and Paranoid)
Slide 9: Ecosystem Explosion
Ecosystem Explosion Competition Great For All (Especially Patients) Gene Therapy (20+) CAR/TCR/T Cell (25+) Gene Editing (8+) Mustang Therapeutics CARsgen
Slide 10: Deepening Pipeline
Deepening Pipeline Product Candidates Prost res| Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Lenti-D™ orto Rare Hemoglobinopathies LentiGlobin” Oncology Five Prime Target Worldwide Kite Pharma HPV-16 E6 TCR Worldwide Viromed Target excluding Korea Other Programs Worldwide » bluebirdb
Slide 11: Asking the Important Questions
Asking the Important Questions What is the β-thalassemia clinical/regulatory path forward? What is the SCD data telling us? What are you doing to improve your platform? What are you doing to build a sustainable pipeline? What is the plan for oncology/BCMA?
Slide 12: LentiGlobin Clinical Data Update
LentiGlobin Clinical Data Update Dave Davidson, M.D. Chief Medical Officer
Slide 13: β-thalassemia Major
β-thalassemia Major
Slide 14: HGB-204 and HGB-205 β-Thalassemia Subjects
As of October 28, 2015 *reasons for ineligibility: advanced liver disease (n=3), positive HBV serology (n=1) Consented N=27 Ineligible N=4* Stem Cell Mobilization N=23 Transduction in Progress N=2 Transduction Complete N=20 Drug Product Infused N=17 Awaiting Infusion N=3 Apheresis Failure N=1 HGB-20
Slide 15: Demographics for Treated Patients with β-Thalassemia Major
Parameter Category HGB-204 (N=13) HGB-205 (N=4) Total (N= 17) Gender (n) M 2 2 4 F 11 2 13 Age (yrs) Median (range) 21 (18-35) 18 (16-19) 20 (16-35) Genotype (n) β0/β0 6 0 6 β0/βE 4 3 7 β0/β+ 1 0 1 β+/β+ 1 1 2 β0/βx 1 0 1 Pre-study pRBC transfusion requirements (ml/kg/year) Median (range) 168 (131-2
Slide 16: Safety Profile: No Drug Product-Related Serious Adverse Events
Incidence of non-hematologic Grade 3-4 AEs, by PT Occurring in ≥ 2 subjects HGB-204 n (%) HGB-205 n (%) Number of subjects 13 4 Stomatitis 9 (69%) 3 (75%) Febrile Neutropenia 7 (54%) 0 Pharyngeal inflammation 4 (31%) 0 Irregular Menses 2 (15%) 0 All AEs consistent with busulfan myeloablative conditi
Slide 17: Engraftment and LVV-Specific Safety
HGB-204 HGB-205 Follow-up period (months) Median 9 (n = 13) (range 0.2 – 19.1) Median 11.4 (n = 4) (range 1.8 – 21) Neutrophil engraftment Median Day +18 (n = 11) (range 13 - 29) Median Day +16 (n = 4) (range 13 – 28) Platelet engraftment Median Day +30 (n = 10) (range 17 - 39) Median Day +21 (n = 4
Slide 18: Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion
Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion As of October 28, 2015. DP VCN for all treated subjects. PBL VCN given for subjects with ≥2 months follow-up DP β0/β0 Non-β0/β0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 5 4 3 2 0 3 6 9 12 15 18 21 1102 1103 1104 1106 1107 1108 110
Slide 19: HbAT87Q Production After Infusion
HbAT87Q Production After Infusion As of October 28, 2015. Only includes subjects with ≥3 months of follow-up Median HbAT87Q g/dL 3.8 5.4 6.7 4.4 N=9 N=13 N=11 N=5 6.1 N=4 7.8 N=3 β0/β0 Non-β0/β0 1102 1103 1104 1106 1107 1108 1109 1110 1111 1113 1201 1202 1203 11 10 9 8 7 6 5 4 3 2 1 0 HbAT87Q Concen
Slide 20: Ongoing Transfusion Independence in Non-β0/β0 Patients
Ongoing Transfusion Independence in Patients with Non- β0/β0 Genotypes with at Least 6 Months Follow Up Days Transfusion-Free Months Transfusion-Free* *as of October 28, 2015 for patients in HGB-204 and November 10, 2015 for patients in HGB-205 Subjects with non-β0/β0 genotypes stop transfusions sho
Slide 21: Reduction in pRBC Transfusions in β0/β0 Genotype
33% to 100% Reduction in pRBC Transfusions Observed in Subjects with β0/β0 Genotype As of October 28, 2015. Subjects with ≥6 m follow-up, shown to latest 3m interval, as of data cut-off. Subjects 1113 & 1115 had <6m follow-up. 52% 47% 33% 100% 1103 1106 1107 1110 Volume Reduced *3-month average numb
Slide 22: Effect of Drug Product VCN on HbAT87Q Expression
Effect of Drug Product VCN on HbAT87Q Expression
Slide 23: Evolving Clinical and Regulatory Plans
Pursue CONDITIONAL APPROVAL on the basis of data from ongoing Northstar (HGB-204) & HGB-205 studies Pursue ACCELERATED APPROVAL on the basis of data from planned pivotal HGB-207 & HGB-208 studies EU U.S. Initial U.S. regulatory strategy will focus on non-β0/β0 patients HGB-207 and likely HGB-208 to
Slide 24: Severe Sickle Cell Disease
Severe Sickle Cell Disease
Slide 25: Why LentiGlobin May Treat Sickle Cell Disease
polymerization destabilization V F L T bs bs V F L Q bs b-87 Why LentiGlobin May Treat Sickle Cell Disease These data suggest that as little as 3g/dL (~30%) of anti-sickling hemoglobin could be functionally curative LentiGlobin incorporates anti-sickling amino acid found in fetal hemoglobin (glutami
Slide 26: HGB-206 Enrollment Update
Patients with severe sickle cell disease Open label, multi-center, U.S. based study Increased enrollment target from 8 subjects to 20 subjects to provide additional data and flexibility for regulatory strategy As of November 17, 2015, 11 subjects enrolled; bone marrow harvest completed for four subj
Slide 27: Severe Sickle Cell Disease Treated Patient Demographics
Severe Sickle Cell Disease Treated Patient Demographics Parameter HGB-205 HGB-206 1204 1301 1303 1306 Gender M F M M Age at enrollment (years) 13 25 42 20 Time since BB305 infusion 13.0 m 3.0 m 5.3 m <1 m SCD Disease History Vaso-occlusive crisis Y Y Y Y Acute chest syndrome Y Y Y Y Tricuspid regurg
Slide 28: Engraftment and Safety Summary
No replication competent lentivirus detected in any subject to date Integration site analysis shows highly polyclonal repopulation with no clonal dominance detected at any time point No AEs assessed to be related to BB305 drug product Data as of 01 Oct 2015. 1.ANC ≥ 500 for 3 consecutive days; 2. Un
Slide 29: HbAT87Q Production and Globin Change after Infusion
HbAT87Q Production and Globin Change after Infusion 1301 1303 1204 10 0 10 0 15 0 Months post drug product infusion Hb g/dL 1 2 3 6 9 12 10.9 12.0 10.6 11.4 11.7 9.1 8.5 7.6 5.5 10 8.6 7.8 9.2 8.5 HbAT87Q HbF HbA2 HbS HbA (transfused) 1.0 0.3 8.6 49% Anti-sickling Hemoglobin 16% Anti-sickling Hemogl
Slide 30: Severe SCD: Subject 1204 Free of Transfusions; No Hospitalizations
Weaned off transfusions Last transfusion on Day + 88 (> 6 months ago) Severe SCD: Subject 1204 Free of Transfusions; No Hospitalizations Transfusions Chronic transfusions Clinical Status Multiple hospitalizations before starting transfusion regimen Pre-Treatment 1 Year After Treatment Data as of Nov
Slide 31: Advancing LentiGlobin in β-thalassemia Major, Building Evidence in Severe SCD
Advancing LentiGlobin in β-thalassemia Major Building Evidence of Benefit in Severe SCD Early transfusion independence data in patients with non-β0/β0 genotypes driving clinical and regulatory strategy Encouraging early transfusion reduction data in patients with β0/β0 genotype, but more data and lo
Slide 32: Research Platform
Research Platform Philip Gregory, D. Phil. Chief Scientific Officer
Slide 33: Research Platform and Strategy
Drive toward sustainable IND engine with ability to feed pipeline for bluebird’s future Research Platform and Strategy mRNA SynBio Lentivirus T Cell HSC Platform T Cell Platform Future Pipeline MegaTALs Strengthening existing platforms HSC Ex Vivo
Slide 34: HSC Platform Research
HSC Platform Research Enhance therapeutic potential of bluebird’s current clinical programs Leverage technology platform advantage to address additional indications Research Platform and Strategy HSC Ex Vivo T Cell HSC Platform T Cell Platform Future Pipeline mRNA SynBio Lentivirus MegaTALs
Slide 35: Hypothesis: Improving VCN in the Drug Product Should Increase T87Q Levels
Hypothesis: Improving VCN in the Drug Product Should Increase T87Q Levels and Further Improve Clinical Benefit
Slide 36: Improving VCN in the Drug Product: Identifying Compounds
Improving VCN in the Drug Product Identifying Compounds that Improve Transduction Goal: Increased VCN via increased transduction efficiency (% HSCs transduced)
Slide 37: Improving VCN in the Drug Product: Selected Compounds
Improving VCN in the Drug Product Selected Compounds from Screening Results Experiment performed with pre-characterized “hard to transduce” donor HSCs Similar fold improvement in VCN obtained across a wide range of donors, lentiviral vectors and LVV lots Process is well tolerated Standard Conditions
Slide 38: Markedly Increased % Corrected HSCs
Improving VCN in the Drug Product Markedly Increased % Corrected HSCs % Transduced Cells Standard Conditions Single-cell PCR assay demonstrates marked increase in transduction efficiency Up to ~90% of the cells transduced using most optimized conditions *preliminary research findings
Slide 39: Increased Transduction Efficiency in Long Term HSC Population
Goal of increased VCN via increased transduction efficiency (% transduced) achieved Legend: Bulk: CD34+ HSC: CD34+CD38LoCD90+CD45RA- Increased Transduction Efficiency Observed in the Most Primitive Long Term HSC Population % Transduced Cells A B + C *preliminary research findings
Slide 40: Improving VCN in the Drug Product Key Takeaways
Improving VCN in the Drug Product Key Takeaways Several different compounds identified that increase VCN in the drug product (both alone and in combination) Importantly, increased VCN is achieved in part by increasing the number of transduced cells (% HSCs carrying LentiGlobin) Long term HSCs show a
Slide 41: T cell Platform Research
T cell Platform Research Intensely competitive space but with potential for transformative benefit Opportunity to exploit breadth of bbb technology platforms to potentially create “best in class” differentiated products Research Platform and Strategy HSC Ex Vivo T Cell HSC Platform T Cell Platform F
Slide 42: Manufacturing of an Enhanced CAR T Cell Product by Inhibiting PI3K/AKT Pathway
Manufacturing of an Enhanced CAR T Cell Product by Inhibiting PI3K / AKT Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells Adoptive Immunotherapy Program: Oral and Poster Abstracts Session: 703. Adoptive Immunotherapy: Poster I Saturday, December 5, 2015,
Slide 43: Example 2: bluebird Gene Editing Approach MegaTAL Technology
Example 2: bluebird Gene Editing Approach MegaTAL Technology Expertise in homing endonucleases (HE) and MegaTALs Robust nuclease discovery platform, proprietary database, broad IP Multiple advantages of HE and MegaTALs Naturally occurring proteins Highly specific and efficient Compact size Broad ran
Slide 44: MegaTAL Driven Genome Editing Outcomes
MegaTAL Driven Genome Editing Outcomes
Slide 45: MegaTAL Platform Drives Efficient Gene Disruption
MegaTAL Platform Drives Efficient Gene Disruption TCRa KO in T cells c - TCRα megaTAL RNA megaTAL megaTAL + Trex2 Efficient megaTAL TCRa gene KO TCRa editing generates more efficacious anti-tumor T cells TCRa KO using bluebird megaTAL platform is fully compatible with current clinic scale process
Slide 46: Improving MegaTAL Design
Improving MegaTAL Design Density 4 bp DNA cleavage site NON-PROGRAMMABLE 12 bp TAL target recognition 18 bp HE target recognition megaTAL: 30 bp fully programmable DNA sequence recognition wild type HE central-4 targetable sequences Improved megaTAL platform enhances applicability across the univers
Slide 47: Future Pipeline
Future Pipeline Leverage academic collaborations to drive early innovative science Build on and extend technology platforms Establish a sustainable pipeline Research Platform and Strategy HSC Ex Vivo T Cell Strengthening existing platforms HSC Platform T Cell Platform Future Pipeline mRNA SynBio Len
Slide 48: Leveraging Select Academic Collaborations
Celgene, bluebird bio, and the Center for Cell and Gene Therapy Combine Strengths and Resources to Develop T-cell Based Therapies for Cancer On March 19, 2013, BCM signed an exclusive multiyear research and collaboration agreement and a platform technology license agreement with Celgene Corporation
Slide 49: Boolean Immunotherapy
Boolean Immunotherapy Turning a Negative T cell Signal into a Positive One No Tx CTL CTL + IL4/7
Slide 50: MegaTAL Enabled Targeted Gene Addition
Demonstrates power of megaTAL and AAV platforms – supports NextGen HSC and Cancer Immunotherapy Programs MegaTAL Enabled Targeted Gene Addition Precision Offers Promise of Enhanced Efficacy and Safety
Slide 51: Research Platform and Strategy Key Takeaways
Research Platform and Strategy Key Takeaways mRNA SynBio Lentivirus T Cell HSC Platform T Cell Platform Future Pipeline MegaTALs Strengthening existing platforms HSC Ex Vivo Powerful research platform with multiple tools and technologies Today highlighted selected efforts to: Enhance the therapeutic
Slide 52: Immuno-Oncology
Immuno-Oncology Richard Morgan, Ph.D. Vice President, Immunotherapy Rob Ross, M.D. Head of Oncology
Slide 53: BCMA: A Promising Target in Multiple Myeloma
B cell maturation antigen (BCMA) is a member of the TNF receptor superfamily. BCMA binds B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA is expressed by plasma cells and some mature B cells. Mice deficient in BCMA are healthy and have normal numbers of B cells, but
Slide 54: bb2121 Vector Design
bb2121 Vector Design SP Anti-BCMA scFv CD3z 41BB MND CD8 bb2121 CAR Expression Control CAR Anti-BCMA CAR Anti-BCMA CAR Expression Anti-BCMA CAR – bb2121
Slide 55: Single Treatment with bb2121 CAR T Cells Clears Animals of MM
Tumor treatment Bortezomib A Single Treatment with bb2121 CAR T Cells Clears Animals of MM and Results in 100% Survival Survival
Slide 56: bb2121 CAR T Cells Infiltrate and Eliminate BCMA+ MM Tumors
bb2121 CAR T Cells Infiltrate and Eliminate BCMA+ MM Tumors In control mice, the BCMA+ MM tumor expands, and no CD3+ cells infiltrate In bb2121 treated mice, the BCMA+ MM tumor regresses; CD3+ CAR T cells infiltrate and eliminate the tumor Brown staining indicates presence of target protein bb2121 C
Slide 57: An Efficient CAR T Drug Product Manufacturing Process
(Day 3-10) Expansion (Day 10) Harvest/Cryopreservation (Day -1) Leukapheresis Gene modified T cells infused back to patient (Day 0) PBMC Isolation, Culture Initiation/Activation (Day 1) Transduction with LVV Gene modified T cells Step 1 Step 2 Step 3 Step 4 Treatment An Efficient CAR T Drug Product
Slide 58: Manipulating T Cell Lineages for Improved Anti-Tumor Activity
Goal: Generate More Efficacious Anti-Tumor T Cells Manipulating T Cell Lineages for Improved Anti-Tumor Activity T Cell Lineages Post-Antigen Stimulation TN Cell TSCM Cell TCM Cell TEM Cell TEFF Cell T Cell Plasticity Self Renewal Long Lived Terminally Differentiated No Self Renewal Short Lived
Slide 59: Improved T Cell Manufacturing
Improved T Cell Manufacturing IL-2 (standard) IL-2 + PI3K inhibitor IL-7 + IL-15 Stress Test Using Hard To Treat Tumor Models
Slide 60: Stress Test 1: Treating an Aggressive Lymphoma
Infuse CAR T cells Day 20 after CAR T Day 35 after CAR T Day 15 after CAR T Day 0, Tumor Cells Stress Test 1: Treating an Aggressive Lymphoma with a Minimal Number of bb2121 T Cells IL-2 IL-2 + PI3K IL-7 + IL-15 Vehicle
Slide 61: Stress Test 2: Cancer Relapse Model
Primary Tumor Treatment Tumor Re-Challenge Re-Challenge With New Tumor Stress Test 2: Use a Cancer Relapse Model as a Measure of bb2121 T Cell Durability and Long-Term Fitness
Slide 62: Deepening Pipeline
Deepening Pipeline Product Candidates Prost res| Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Lenti-D™ orto Rare Hemoglobinopathies LentiGlobin” Oncology Five Prime Target Worldwide Kite Pharma HPV-16 E6 TCR Worldwide Viromed Target excluding Korea Other Programs Worldwide » bluebirdb
Slide 63: Promising Proof of Concept for bb2121 from NCI
Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender
Slide 64: Promising Proof of Concept for bb2121 from NCI
Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender
Slide 65: Promising Proof of Concept for bb2121 from NCI
Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender
Slide 66: Promising Proof of Concept for bb2121 from NCI
Promising Proof of Concept for bb2121 from NCI Latebreaker with Other Anti-BCMA CAR T Therapy Data from NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma as presented at ASH 2015 press conference Presenter and PI Jim Kochender
Slide 67: CRB-401 (Refractory Multiple Myeloma): First Oncology Clinical Trial
U.S.-based, 6-10 clinical sites – including NCI N = 40 patients, standard 3+3 Design based on CAR+ T cells doses Primary endpoint = Determine the maximally tolerated dose and recommended phase 2 dose (RP2D) Subjects must have received 3 prior regimens including a proteasome inhibitor (bortezomib, ca
Slide 68: Differentiated Oncology Approach
Deliver differentiated, best-in-class, genetically modified cellular products to patients suffering from cancer. Differentiated Oncology Approach BCMA (Partnered with Celgene) HPV Partnered with Kite Five Prime Target Viromed Target LVV Technology Manufacturing Advances (Pl3K) LVV Technology Manufac
Slide 69: Differentiated Oncology Approach
Deliver differentiated, best-in-class, genetically modified cellular products to patients suffering from cancer. Five Prime Target Viromed Target BCMA (Partnered with Celgene) HPV Partnered with Kite Differentiated Oncology Approach
Slide 70: Closing
Closing Nick Leschly Chief Bluebird
Slide 71: Asking the Important Questions
Asking the Important Questions What is the β-thalassemia clinical/regulatory path forward? What is the SCD data telling us? What are you doing to improve your platform? What are you doing to build a sustainable pipeline? What is the plan for oncology/BCMA?
Slide 72: bluebird bio 2020: The Gene Therapy Products Company
2010 - 2014 bluebird bio 2020: The Gene Therapy Products Company 2015 - 2020 Early POC Clinical Data Infrastructure & Capabilities Core Program Clinical Data Broad Gene Therapy Infrastructure Translational Development Manufacturing Clinical Regulatory Tech & Global Collaborations and New Products Gl
Slide 73: Q&A
Q&A